Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Gefitinib versus placebo in oesophageal cancer progressing after chemotherapy

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.09.12
Views: 8010
Rating:

Prof David Ferry - New Cross Hospital, Wolverhampton, UK

New trial data showing improvements in the treatment of oesophageal and gastrointestinal cancers were presented at a press conference at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

 

The first phase III trial to address the need for second-line treatments in oesophageal cancer shows that gefitinib improves important quality-of-life measures and extends progression-free survival, UK researchers report.

 

A further study, TRANSCOG, is planned to analyse over 300 patients’ biopsies in an effort to identify a molecularly defined subgroup where the benefit is enriched, said study author Prof David Ferry from New Cross Hospital in Wolverhampton, UK.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation